Lung cancer gene map after drug failure could guide next steps

NCT ID NCT05219162

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at gene changes in 182 people with advanced lung cancer whose disease got worse after first-line treatment with Osimertinib. Researchers collected tissue and blood samples to understand why the drug stopped working. The goal is to use this information to help choose better treatments for these patients in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose better second-line treatments for lung cancer patients whose disease progresses after Osimertinib.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NSCLC

Contacts and locations

Locations

Research Site

Beijing, 100210, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610014, China
Research Site

Dalian, 116023, China
Research Site

Foshan, 528000, China
Research Site

Fuzhou, 350014, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230001, China
Research Site

Hefei, 230601, China
Research Site

Linhai, 317000, China
Research Site

Luoyang, 471003, China
Research Site

Rizhao, 276826, China
Research Site

Shanghai, 200032, China
Research Site

Taizhou, 225300, China
Research Site

Tianjin, 300060, China
Research Site

Zhengzhou, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.